Clinical Development Program Utilizing Xenomics' DNA-Based Diagnostic Technology is Ranked Best in Europe
Complete the form below to unlock access to ALL audio articles.
Xenomics, Inc. has announced that a clinical development program utilizing Xenomics' DNA-based diagnostic technology was ranked by the European Commission as among the best technology development programs in the European Union.
SpaXen, Xenomics' collaborative venture with Italy's National Institute for Infectious Diseases (INMI), leads an international Consortium focusing on the development of a diagnostic test for tuberculosis utilizing Xenomics' DNA technology.
The Consortium is currently in the final contract negotiation phase in preparation for euro 2.0 million in funding by the European Commission for the development of this test.
"Commercially successful testing methods for detecting and monitoring tuberculosis infections have not appreciably changed in fifty years," commented Dr. L. David Tomei, PhD., Xenomics' CEO and co-founder.
"Xenomics' non-invasive, urine-based DNA diagnostic technology will foster fundamental improvements in safety, accuracy and functionality of diagnostic testing for tuberculosis."
"The benefit of early detection of tuberculosis infections is obvious," says Dr. Enrico Girardi, a leading tuberculosis researcher with INMI.
"However, it is important to note that the non-invasive aspect of Xenomics' urine-based technology makes it ideal for ongoing monitoring of tuberculosis infections which require repeated tests to ensure complete eradication."
"Xenomics' technology is based upon the fact that cellular DNA from throughout the body cross the kidney barrier and accumulate in the urine," said Dr. Tomei.
Through the analysis of easily obtained urine samples from patients, these Transrenal DNA fragments (Tr-DNA) are designed to provide vital information about a wide range of conditions inside the body, including serious infectious diseases.
